KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Free Cash Flow (2017 - 2025)

Twist Bioscience (TWST) has disclosed Free Cash Flow for 7 consecutive years, with -$19.8 million as the latest value for Q3 2023.

  • On a quarterly basis, Free Cash Flow fell 125.43% to -$19.8 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$143.2 million, a 9.61% decrease, with the full-year FY2025 number at -$50.0 million, up 27.66% from a year prior.
  • Free Cash Flow was -$19.8 million for Q3 2023 at Twist Bioscience, down from -$4.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $77.8 million in Q3 2022 to a low of -$74.8 million in Q2 2022.
  • A 5-year average of -$33.9 million and a median of -$32.9 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 149.8% in 2020, then soared 281.46% in 2022.
  • Twist Bioscience's Free Cash Flow stood at -$37.0 million in 2019, then grew by 22.75% to -$28.6 million in 2020, then plummeted by 108.1% to -$59.4 million in 2021, then dropped by 10.87% to -$65.9 million in 2022, then soared by 69.97% to -$19.8 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Free Cash Flow are -$19.8 million (Q3 2023), -$4.2 million (Q2 2023), and -$53.3 million (Q1 2023).